What is Esperion Therapeutics's investing cash flow?

Esperion Therapeutics (ESPR) reported investing cash flow of -$189K in Q1 2026.

What is the long-term trend for Esperion Therapeutics's investing cash flow?

Over 2 years (2021 to 2025), Esperion Therapeutics's investing cash flow has grown at a -100.0% compound annual growth rate (CAGR), from -$50.48M to $0.

What does investing cash flow mean?

Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Esperion Therapeutics ESPR Investing Cash Flow

Investing Cash Flow at other companies

AmgenAMGN

-$716M-60.2%

Regeneron PharmaceuticalsREGN

-$428.9M-166%

NewAmsterdam Pharma CompanyNAMS

-$11.51M-503%

Lexicon PharmaceuticalsLXRX

-$70.26M-273%

Zevra Therapeutics, Inc.ZVRA

$79.62M+655%

Eton Pharmaceuticals, Inc.ETON

-$15.08M—

Other financials

Income statement

See full

Revenue$80.1M+23.2%

Operating income-$6.6M+70.2%

Net income-$25.2M+37.7%

EPS (diluted)-$0.10+52.4%

Balance sheet

See full

Cash & equivalents$156.2M+36.2%

Total debt$155.2M+6.1%

Total equity-$307.9M+27.8%

Total assets$462.5M+42.7%

Cash flow

See full

Operating cash flow-$27.7M-22.5%

CapEx$189.0K—

Free cash flow-$27.9M-23.3%

Valuation

See full

Market cap$811.73M+283%

Enterprise value$810.81M+233%

P/S1.9×+1.1×

Profitability

See full

Operating margin18.1%+12.7pp

Net margin-34.8%+8.0pp

FCF margin-30.7%—

Returns & leverage

See full

Return on equity-260.8%—

Debt / equity0.8×—

Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Esperion Therapeutics's investing cash flow?: Esperion Therapeutics (ESPR) reported investing cash flow of -$189K in Q1 2026.
What is the long-term trend for Esperion Therapeutics's investing cash flow?: Over 2 years (2021 to 2025), Esperion Therapeutics's investing cash flow has grown at a -100.0% compound annual growth rate (CAGR), from -$50.48M to $0.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.